Journal
UROLOGIC CLINICS OF NORTH AMERICA
Volume 42, Issue 2, Pages 235-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ucl.2015.01.005
Keywords
Bladder cancer; Alvimopan; Blue-light cystoscopy; Robotic cystectomy; Costs; Quality of life
Categories
Ask authors/readers for more resources
Bladder cancer is the most expensive cancer to treat from diagnosis to death. Frequent disease recurrence, intense follow-up, and expensive, invasive techniques for diagnosis and treatment drive these costs for non-muscle invasive bladder cancer. Fluorescence cystoscopy increases the detection of superficial bladder cancer and reduces costs by improving the quality of resection and reducing recurrences. Radical cystectomy with intestinal diversion is the mainstay of treatment of invasive disease; however it is associated with substantial cost and morbidity. Increased efforts to improve the surgical management of bladder cancer while reducing the cost of treatment are increasingly necessary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available